The Oncolines anti-cancer agent reference library includes drug response profiles of a large, diverse set of anti-cancer agents. The drug response profiles are derived from viability assays in our panel of 102 cancer cell lines. We have extended this reference library to now include data of more than 270 compounds. The update adds new mechanisms of action to the reference library, such as that of RAS(ON) inhibitors, and expands several modality classes. For example, the classes of degraders and antibody–drug conjugates now include five and seven agents, respectively. Additionally, some new targets (e.g., WRN and CDK2) are covered with the update.

The anti-cancer agent reference library holds valuable data that can be used for various analyses. It is for example the foundation of the OncolinesProfiler™ service, one of our established bioinformatics analyses, in which the sensitivity profile of a compound of interest is compared with the sensitivity profiles of the complete reference library. Using this analysis, the target for a compound may be elucidated, since compounds that target the same biological pathways often have a similar sensitivity profile in a panel of cancer cell line viability assays [1]. Additionally, this analysis allows for comprehensive comparison between competitor compounds.

Reference:
[1] Uitdehaag et al. (2016). Cell panel profiling reveals conserved therapeutic clusters and differentiates the mechanism of action of different PI3K/mTOR, Aurora kinases and EZH2 inhibitors. Molecular Cancer Therapeutics 15, 3097–3109.